ConductScience.org, home

Paper29463528

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R and 10 others. Antimicrob Agents Chemother, 2018. Cited by 21 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Papers, record 29463528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29463528

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2019-06-18
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yadav RRajbharanhttps://orcid.org/0000-0002-4608-8744
2Rogers KEKate E
3Bergen PJPhillip J
4Bulitta JBJürgen Bhttps://orcid.org/0000-0001-7352-3097
5Kirkpatrick CMJCarl M J
6Wallis SCSteven C
7Paterson DLDavid L
8Nation RLRoger L
9Lipman JJeffrey
10Roberts JAJason A
11Landersdorfer CBCornelia B

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
PiperacillinMajor topic
Pseudomonas aeruginosaMajor topic
TobramycinMajor topic
Humans
Microbial Sensitivity Tests
Models, Theoretical

Source PubMed

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120,000,886Augmented renal clearance: implications for antibacterial dosing in the critically ill.Clin Pharmacokinet2010https://conductscience.org/library/papers/20000886PubMed
220,463,340Hospital-acquired infections due to gram-negative bacteria.N Engl J Med2010https://conductscience.org/library/papers/20463340PubMed
328,264,846Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28264846PubMed
424,760,199Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.J Infect Dis2014https://conductscience.org/library/papers/24760199PubMed
526,433,783
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
J Antimicrob Chemother2016https://conductscience.org/library/papers/26433783PubMed
66,794,444Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6794444PubMed
710,868,299[In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].Jpn J Antibiot2000https://conductscience.org/library/papers/10868299PubMed
829,180,527Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29180527PubMed
924,429,437DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?Clin Infect Dis2014https://conductscience.org/library/papers/24429437PubMed
106,810,755Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6810755PubMed
113,909,952Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.Antimicrob Agents Chemother1985https://conductscience.org/library/papers/3909952PubMed
127,637,145The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.JAMA1995https://conductscience.org/library/papers/7637145PubMed
1319,157,339You only find what you look for: the importance of high creatinine clearance in the critically ill.Anaesth Intensive Care2009https://conductscience.org/library/papers/19157339PubMed
1420,516,275Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20516275PubMed
1525,632,974Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Crit Care2015https://conductscience.org/library/papers/25632974PubMed
1621,143,502Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.Br J Clin Pharmacol2011https://conductscience.org/library/papers/21143502PubMed
1711,978,497Animal model pharmacokinetics and pharmacodynamics: a critical review.Int J Antimicrob Agents2002https://conductscience.org/library/papers/11978497PubMed
1828,052,852High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28052852PubMed
1921,369,876Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.AAPS J2011https://conductscience.org/library/papers/21369876PubMed
2021,769,107Implications of augmented renal clearance in critically ill patients.Nat Rev Nephrol2011https://conductscience.org/library/papers/21769107PubMed

See all 72 references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42,787,356Source Control in Pseudomonas aeruginosa Bloodstream Infections: An Overlooked Pillar in Reducing 30-Day All-Cause Mortality.Open Forum Infect Dis2026https://conductscience.org/library/papers/42787356PubMed
40,372,038A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data.Microbiol Spectr2025https://conductscience.org/library/papers/40372038PubMed
38,236,031Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa.mBio2024https://conductscience.org/library/papers/38236031PubMed
37,564,179Individualized antibiotic dosage regimens for patients with augmented renal clearance.Front Pharmacol2023https://conductscience.org/library/papers/37564179PubMed
36,125,299A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36125299PubMed
35,924,928Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35924928PubMed
35,890,380The Application of Hollow Fiber Cartridge in Biomedicine.Pharmaceutics2022https://conductscience.org/library/papers/35890380PubMed
35,052,977
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.
Antibiotics (Basel)2022https://conductscience.org/library/papers/35052977PubMed
34,156,288Filamentous Bacteriophages and the Competitive Interaction between Pseudomonas aeruginosa Strains under Antibiotic Treatment: a Modeling Study.mSystems2021https://conductscience.org/library/papers/34156288PubMed
32,131,897Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.BMC Pharmacol Toxicol2020https://conductscience.org/library/papers/32131897PubMed
31,636,062Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/31636062PubMed
30,912,119Pharmacodynamic Drug-Drug Interactions.Clin Pharmacol Ther2019https://conductscience.org/library/papers/30912119PubMed
30,104,278Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/30104278PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29463528

GET https://conductscience.org/api/papers/v1/29463528/references?page=2